Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEVER
NCT05175547Phase 3Completed
- Sponsor
- Promedica International
- Start
- Oct 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of clevidipine in ischemic stroke and hypertensive crisis (2 arms), sponsored by Promedica International. Primary endpoints: Time from drug initiation to target blood pressure at 24 hours and Primary Safety Endpoint at 24 hours. Started Oct 2021; status: completed.
02
Drugs
clevidipine
03
Conditions
ischemic strokehypertensive crisis
Beyond the preview
Go deeper on NCT05175547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175547.